SAFE-PAD evaluated the real-world safety of femoropopliteal artery revascularization using drug-coated vs non-drug-coated devices.
Your search for comorbidities returned 88 results
Click on a filter below to refine your search. Remove a filter to broaden your search.
A systematic review and meta-analysis was conducted to look at the effects of body mass index on atrial fibrillation‐related outcomes in anticoagulated patients.
Researchers investigate the potential prognostic predictor of TSB on COVID-19 mortality as well as the demographic and characteristics of this population.
Sodium-glucose cotransporter 2 inhibitors use may reduce cardiac arrhythmia risk, including the risk for atrial fibrillation.
Statins may play an important role in combating inflammation in COVID-19.
Researchers assessed the clinical usefulness of specific biomarkers in risk stratification for vascular complications Identifying biomarkers that predict risk for pulmonary hypertension or ischemic digital lesions may be useful in monitoring the development of systemic sclerosis in patients.
Management of patients with a recently implanted left ventricular assist device necessitates a thorough understanding of the postimplant period and of common critical care issues that may arise from the operating room to critical care discharge.
Women who smoke may be at higher risk of developing abdominal aortic aneurysm compared with men who do not smoke.
In patients hospitalized for COPD exacerbation, the presence of atrial fibrillation may increase the risk of in-hospital mortality.
The risk for death in patients undergoing anticoagulation therapy for venous thromboembolism was found to be lower in those who were morbidly obese vs those who had normal weight.